Drug Trial Radar · NCT07813572
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Sep 2031
Study completion Sep 2032
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
Conditions
- Hepatocellular Carcinoma
Interventions
ZG005 for InjectionDrug
Participants receive ZG005 20 mg/kg IV, Q3W
Bevacizumab ( Avastin)Drug
Participants receive Bevacizumab ( Avastin) 15 mg/kg IV, Q3W
SintilimabDrug
Participants receive Sintilimab 200mg IV, Q3W
BevacizumabDrug
Participants receive Bevacizumab 15 mg/kg IV, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: up to 3 years
- Overall survival (OS)Time frame: up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.